BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC. revenue, earnings and financials
For the quarter ended June 30, 2026, BIOFORCE NANOSCIENCES HOLDINGS, INC. reported revenue of n/a, net income of $239K and diluted EPS of $0.01; for the fiscal year ended December 2025 revenue was n/a.
BFNH annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$1.29M (margin n/a), EPS −$0.04
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$490K (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$472K (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$486K (margin n/a), EPS −$0.02
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$502K (margin n/a), EPS −$0.02
BFNH quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $239K, EPS $0.01
- Quarter ended Mar 31, 2026: revenue n/a, net income −$102K, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$118K, EPS −$0.01
- Quarter ended Sep 30, 2025: revenue n/a, net income −$116K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue n/a, net income −$123K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$935K, EPS −$0.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$123K, EPS −$0.02
- Quarter ended Sep 30, 2024: revenue n/a, net income −$122K, EPS $0.00
- Quarter ended Jun 30, 2024: revenue n/a, net income −$114K, EPS $0.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$131K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$114K, EPS −$0.02
- Quarter ended Sep 30, 2023: revenue n/a, net income −$114K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue n/a, net income −$114K, EPS $0.00
- Quarter ended Mar 31, 2023: revenue n/a, net income −$130K, EPS $0.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$115K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$123K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue n/a, net income −$116K, EPS $0.00
- Quarter ended Mar 31, 2022: revenue n/a, net income −$132K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$121K, EPS −$0.02
- Quarter ended Sep 30, 2021: revenue n/a, net income −$114K, EPS $0.00
BFNH cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$65.2K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$61.3K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$46.7K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$68.4K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$77.8K, share buybacks n/a
BFNH balance sheet
- Jun 30, 2026: cash $307, total assets $2.39M, total liabilities $84.8K, shareholders' equity $2.30M
- Mar 31, 2026: cash $6.35K, total assets $6.35K, total liabilities $727K, shareholders' equity −$721K
- Dec 31, 2025: cash $786, total assets $786, total liabilities $619K, shareholders' equity −$619K
- Sep 30, 2025: cash $784, total assets $784, total liabilities $501K, shareholders' equity −$500K
- Jun 30, 2025: cash $905, total assets $905, total liabilities $385K, shareholders' equity −$384K
- Mar 31, 2025: cash $13.8K, total assets $13.8K, total liabilities $275K, shareholders' equity −$261K
- Dec 31, 2024: cash $862, total assets $862, total liabilities $2.30M, shareholders' equity −$2.30M
- Sep 30, 2024: cash $1.64K, total assets $1.64K, total liabilities $2.18M, shareholders' equity −$2.18M
Is BFNH profitable?
No. BIOFORCE NANOSCIENCES HOLDINGS, INC. lost $97.4K over the last four quarters.
What is BFNH's EPS?
Diluted earnings per share over the last four quarters were $0.00; $0.01 in the latest quarter.